For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Leverage Ranbaxy’s Network to Market Its Innovative Products in Singapore

March 1, 2011, Tokyo, Japan and Gurgaon, India - Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the start of synergistic initiative to leverage Ranbaxy’s presence in Singapore to market innovative products originally discovered by Daiichi Sankyo.

 

Effective March 1, 2011, Ranbaxy will market four products of Daiichi Sankyo origin, including Cravit® (levofloxacin) tab and Cravit® IV in Singapore. The products were previously commercialized by Kyowa Hakko Bio Singapore Pte Ltd (hereafter, Kyowa Hakko Bio) in the country. Early this year, Daiichi Sankyo and Kyowa Hakko Bio had agreed to transfer the marketing rights of the products from Kyowa Hakko Bio to Ranbaxy.

 

“We are pleased to announce the first synergistic business development with Ranbaxy in ASEAN,” said Joji Nakayama, President & CEO of Daiichi Sankyo. “We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging region.”

 

Commenting on the development, Arun Sawhney, Managing Director of Ranbaxy, said, “Ranbaxy has a strong foot hold in the ASEAN region. We will use our marketing strengths to offer innovative medicines from Daiichi Sankyo in this fast growing region, beginning with Singapore. This move will definitely widen our product offering while deepening our commitment to doctors and patients. I believe we will see many more synergies in time, emerging from our Hybrid Business Model with Daiichi Sankyo.”  

    

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. Originally discovered by Daiichi Sankyo, levofloxacin was first launched in Japan in 1993 under the brand name Cravit®. Levofloxacin is currently available in more than 120 countries worldwide.

 

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

 

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.